R&D Net Treatment Benefit in rare disease trials: Aligning trial... Net Treatment Benefit provides a formal framework to integrate multiple prioritised outcomes into a single measure of overall treatment effect.
R&D Sponsored Webinar recap: The future of cell and gene therapy in rare d... For decades, treatment options for rare diseases have been limited, often focusing on symptom management rather than addressing the root cause of them
R&D On a journey to diverse, inclusive, and more efficient rare ... Although orphan drugs represent a sizeable portion of new drug approvals,1most rare diseases still lack effective treatment.
News Senju launches first-in-class dry eye disease drug in Japan Senju has launched a new drug for dry eye disease (DED) in Japan, Avarept, the first drug in the TRPV1 antagonist class to reach the market.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.